Ind-Swift Laboratories enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


3,291	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
385	442	467	432	18.2
−0.1	−0.1	−0.0	−0.0	0.0
17.9	17.9	40.6	16.6	862
2,923	—	—	—	—
−367	−424	−427	−415	843
₹336.63	—	—	—	—

1,492	1,402	1,214	948	1,543
1.2%	1.3%	3.3%	1.8%	55.8%
0.01×	—	—	—	—

3.88×	—	—	—	—
28.20×	—	—	—	—
40.98×	—	—	—	—
753	641	562	1,281	1,207
104	45.1	−19.4	254	229
71.3	14.5	−43.9	201	172
—	−63.2	−25.5	−181	195
−151	−151	−89.9	−225	182
—	−152	−91.1	−258	124
—	87.7	64.4	44.5	12.8

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDSWFTLAB₹378.95

Ind-Swift Laboratories Limited

· Pharma & Health

₹ CrorePeersSMSPHARMA SOLARA DCAL HIKAL UNICHEMLAB GUFICBIO PANACEABIO RPGLIFEMcap ₹3,291 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	3,290.7
- Cash, Equiv & ST Investments	18.2	431.9	467.4	441.8	385.4
+ Minority Interest	0.0	-0.0	-0.0	-0.1	-0.1
+ Total Debt	861.5	16.6	40.6	17.9	17.9
Enterprise Value	—	—	—	—	2,923.2
Net Debt (memo)	843.3	-415.3	-426.8	-423.8	-367.5
EV per Share	—	—	—	—	336.63

Total Capital	1,543.5	948.1	1,213.6	1,401.9	1,492.2
Total Debt/Total Capital	55.82	1.75	3.35	1.28	1.20
Total Debt/EV	—	—	—	—	0.01

EV/Sales	—	—	—	—	3.88
EV/EBITDA	—	—	—	—	28.20
EV/EBIT	—	—	—	—	40.98
Reference Items — Trailing FY Values
Sales	1,207.3	1,280.9	561.7	641.3	752.6
EBITDA	229.2	254.2	-19.4	45.1	103.6
EBIT	171.8	200.9	-43.9	14.5	71.3
Operating Cash Flow	194.6	-180.9	-25.5	-63.2	—
Free Cash Flow	181.8	-225.4	-89.9	-150.9	-150.9
FCFF (free cash flow to the firm)	124.4	-258.2	-91.1	-151.8	—
Capital Expenditure	12.8	44.5	64.4	87.7	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.